Pinealon Peptide Research: Glu-Asp-Arg Neuroprotection, Nuclear DNA Interaction, and Preclinical Antioxidant Evidence

Pinealon peptide research concerns the synthetic tripeptide Glu-Asp-Arg (EDR), a short peptide from the bioregulator series developed by Vladimir Khavinson’s group in St. Petersburg. In preclinical work it restricts reactive oxygen species accumulation in neuronal and immune cells under oxidative stress, reduces necrotic cell death, and enters the cell nucleus where it interacts with DNA in a sequence-dependent way (Khavinson et al., 2011, Rejuvenation Research 14:535-541; Fedoreyeva et al., 2011, Biochemistry (Moscow) 76:1210-1219). This article summarises what has been established in vitro and in animal models, what remains hypothesis, and which analytical entries on a Certificate of Analysis are specific to a three-residue peptide of this composition. A note on nomenclature first: pinealon is frequently confused online with epitalon, the tetrapeptide Ala-Glu-Asp-Gly. The two are different molecules with different masses and different literatures, and any source that describes pinealon as a tetrapeptide is describing the wrong compound.

Identity: a tripeptide, not a tetrapeptide

Pinealon is Glu-Asp-Arg, three residues with a monoisotopic mass close to 418 Da. Its net charge at neutral pH is negative overall because of the two acidic side chains, with the C-terminal arginine contributing a positive centre, which gives the molecule an amphipathic charge pattern that the Khavinson group has argued underlies its affinity for the DNA-histone complex. Epitalon (Ala-Glu-Asp-Gly, about 390 Da) shares the Glu-Asp core and is studied by the same laboratories, but it is a separate compound with its own pineal and telomerase-related literature. Researchers comparing published results should confirm which peptide a paper actually used, because early Russian-language work is often cited in English secondary sources with the two names transposed.

For analytical purposes the identity check is straightforward. Electrospray mass spectrometry should show a protonated molecular ion consistent with the EDR sequence, and reversed-phase HPLC at low wavelength (210 to 220 nm) is used for purity because the peptide contains no aromatic residue and therefore no useful absorbance at 280 nm. A report that quotes 280 nm purity for this compound is a red flag. Our guide to reading a Certificate of Analysis explains how detection wavelength affects the purity figure.

Antioxidant and cytoprotective activity in cell models

The most direct mechanistic study is Khavinson and colleagues (2011, Rejuvenation Research 14:535-541). Using cerebellar granule cells, neutrophils and PC12 pheochromocytoma cells exposed to oxidative stress triggered by either receptor-dependent or receptor-independent stimuli, the authors reported a concentration-dependent restriction of reactive oxygen species accumulation by pinealon, together with a reduction in necrotic cell death measured by propidium iodide uptake. The protective effect was accompanied by a delayed time course of ERK1/2 activation and a shift in cell-cycle distribution. The authors drew a specific inference from the concentration dependence: restriction of ROS accumulation and cell mortality saturated at lower peptide concentrations, whereas the cell-cycle effect continued to change at higher concentrations. They took that divergence as evidence that, beyond a general antioxidant action, pinealon interacts directly with the cell genome.

That inference is consistent with the group’s later summary of EDR work (Khavinson et al., 2020, Molecules 26:E159), which reviews evidence that the tripeptide activates expression of genes and synthesis of proteins involved in maintaining neuronal function, reduces apoptosis intensity in vitro and in vivo, interferes with the elimination of dendritic spines in neuronal cultures derived from mouse models of Alzheimer’s and Huntington’s disease, and promotes synthesis of antioxidant enzymes in cultured rat cerebellar neurons. The review proposes that the peptide enters cells and binds histone proteins and/or ribonucleic acids, and that through that route it can alter MAPK/ERK signalling, the pro-apoptotic proteins caspase-3 and p53, the antioxidant enzymes SOD2 and GPX1, the transcription factors PPARA and PPARG, and serotonin and calmodulin levels. Those are the molecular targets that the Khavinson group has proposed; independent replication outside that group remains limited, and readers should weigh the evidence accordingly.

Nuclear entry and DNA interaction

Fedoreyeva, Kireev, Khavinson and Vanyushin (2011, Biochemistry (Moscow) 76:1210-1219) addressed the question of whether a peptide this small can reach the nucleus at all. After incubating HeLa cells with fluorescein isothiocyanate-labelled epitalon, pinealon and testagen (Lys-Glu-Asp-Gly), they observed marked fluorescence in the cytoplasm, nucleus and nucleolus for each peptide, showing that short biologically active peptides can cross the plasma and nuclear membranes and are in principle able to interact with cytoplasmic and nuclear components including DNA and RNA. In the same study, the unlabelled peptides quenched the fluorescence of carboxyfluorescein-labelled deoxyribooligonucleotides and of DNA-ethidium bromide complexes to differing degrees, and the Stern-Volmer quenching constants for single- and double-stranded oligonucleotides differed according to peptide primary structure. The authors read that as sequence-dependent recognition of DNA by the peptides rather than non-specific electrostatic binding.

A systematic review from the same group (Khavinson et al., 2021, Molecules 26:7053) places pinealon within a broader claim that short peptides of two to seven residues penetrate the nucleus and nucleolus, interact with the nucleosome, histone proteins and single- and double-stranded DNA, and can regulate DNA methylation status. A companion review (Khavinson et al., 2022, International Journal of Molecular Sciences 23:7733) systematises the transport side: di- and tripeptides are carried into cells predominantly by the POT family transporters PEPT1, PEPT2, PHT1 and PHT2, and molecular modelling indicates that LAT1 can also transfer some di- and tripeptides across the membrane. For a tripeptide such as pinealon, carrier-mediated uptake through these transporters is the most plausible route into cells, which distinguishes it mechanistically from larger peptides that depend on receptor binding at the cell surface. Whether specific binding constants for pinealon-histone or pinealon-DNA interaction have been measured is not established in the accessible literature, and figures quoted for them should be traced to a primary source before being cited.

Animal-model evidence

Two rodent studies are accessible in indexed journals. Arutjunyan and colleagues (2012, International Journal of Clinical and Experimental Medicine 5:179-185) used a model of prenatal hyperhomocysteinemia produced by loading pregnant rats with dietary methionine. Administering pinealon to the methionine-loaded dams improved spatial orientation and learning ability in the offspring, and neurons isolated from the offspring cerebellum showed reduced reactive oxygen species accumulation and fewer necrotic cells than neurons from untreated hyperhomocysteinemic offspring. The authors describe the result as confirming in vivo the neuroprotective properties previously seen in vitro.

Mendzheritsky, Karantysh, Ryzhak and Prokofiev (2015, Advances in Gerontology 28:532-539) compared pinealon with cortexin, a polypeptide complex, in 18-month-old rats subjected to acute hypobaric hypoxia or mild hypothermia. Cortexin had the more pronounced effect on free-radical processes and caspase-3 activity in brain, while both preparations increased adrenergic mediator accumulation in the brain under hypoxia and serotonin in the cerebral cortex under hypothermia. The paper is useful precisely because it reports a comparison in which pinealon was not the stronger agent on the oxidative endpoints, which is a check against reading the cell-culture literature as a uniform story.

Claims that circulate online about pinealon in accelerated-senescence mouse strains, in retinal ganglion cell survival, or in radiolabelled brain-distribution studies with quoted brain-to-plasma ratios could not be located in indexed journals during preparation of this article. They are omitted here for that reason, and a previous version of this page that carried them has been corrected.

Storage and degradation considerations specific to Glu-Asp-Arg

The aspartyl residue in the middle of the sequence is the chemical weak point. Aspartic acid adjacent to a small or flexible residue is prone to succinimide formation, which leads to isoaspartate and to cleavage at the Asp-X bond, and the rate rises with moisture, elevated temperature and pH away from the slightly acidic optimum. Glutamic acid at the N-terminus can cyclise to pyroglutamate under some conditions. Both pathways produce impurities that co-elute close to the parent on reversed-phase HPLC and are easy to under-report without a well-resolved method. Our articles on peptide degradation pathways and impurity reporting thresholds cover what a report should show for related substances of this kind. Lyophilised material stored cold, dry and protected from light is the standard recommendation for short peptides carrying an aspartyl residue; see our guide to research peptide storage and handling.

Related neuropeptide research

Pinealon sits within a group of short regulatory peptides studied for central nervous system effects in animal models. Readers working across that group may find our reviews of DSIP antioxidant and stress-protective mechanisms, Semax neurotrophic pathways and Selank GABAergic modulation useful for comparison, since each shares the pattern of a short sequence with proposed transcriptional effects. The Semax vs Selank comparison sets out how two such peptides are distinguished experimentally.

Third-party analytical reports for tested batches are published on our Certificates of Analysis page, and the research peptide catalogue lists the compounds currently available to Canadian laboratories.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

For peer-reviewed research on this topic, visit PubMed.